Allogeneic transplantation still remains as standard of care for patients with high-risk hematological malignancies at diagnosis or after relapse. However, GvHD remains yet as the most relevant clinical complication in the early post-transplant period. TCD allogeneic transplant is now considered a valid option to reduce severe GvHD and to provide a platform for cellular therapy to prevent relapse disease or to treat opportunistic infections.
Keywords: GvHD; GvL effect; T-cell depletion; adoptive cellular therapy; allogeneic transplantation; donor lymphocyte infusion; graft manipulation; haploidentical transplantation.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.